Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Neurosurgery, The Affiliated Jiangyin Hospital, School of Medicine, Southeast University, Jiangyin, China.
Eur Neurol. 2022;85(2):85-94. doi: 10.1159/000520085. Epub 2021 Nov 24.
The combination of mechanical thrombectomy (MT) and intravenous thrombolysis (IVT) is more effective than IVT alone in patients with large vessel occlusion, which has been proven in recent studies. However, there are still debates over whether IVT benefits patients treated with only direct mechanical thrombectomy (dMT).
PubMed, Embase, and Cochrane Library were searched on June 15, 2021, for randomized controlled trials (RCTs). Seven RCTs with 2,143 patients were enrolled in our study.
MT combined with IVT had comparable efficacy and safety outcome compared with dMT in proximal anterior circulation occlusion at 90 days. For the primary outcome, pooled data showed no significant difference in the modified Rankin Scale (mRS) 0-2 at 90 days between the dMT and MT+IVT groups (pooled odds ratio 0.96, 95% confidence interval, 0.79, 1.17, p = 0.39). As for the mRS score 0-1 at 90 days, the degree of benefit conferred by dMT was substantial: for every 100 patients treated, the number of patients which had an excellent outcome in the dMT group was 10 higher than that of the MT+IVT group.
In this meta-analysis including 7 RCTs, MT had comparable consequences to bridging treatment in efficacy and safety outcomes for patients with ischemic stroke caused by the occlusion of proximal anterior circulation, irrespective of geographical location. These findings support the adoption of dMT in acute ischemic stroke treatments and have higher cost-effectiveness in global applications.
在大血管闭塞的患者中,机械血栓切除术(MT)联合静脉溶栓(IVT)比单独 IVT 更有效,这已在最近的研究中得到证实。然而,对于仅接受直接机械血栓切除术(dMT)治疗的患者,IVT 是否有益,仍存在争议。
于 2021 年 6 月 15 日检索 PubMed、Embase 和 Cochrane Library,纳入随机对照试验(RCT)。我们的研究共纳入了 7 项 RCTs 共 2143 例患者。
在近端前循环闭塞患者中,MT 联合 IVT 与 dMT 的疗效和安全性结局相当。对于主要结局,汇总数据显示 90 天 mRS 0-2 评分在 dMT 和 MT+IVT 组之间无显著差异(合并优势比 0.96,95%置信区间 0.79,1.17,p=0.39)。对于 90 天 mRS 评分 0-1,dMT 的获益程度较大:每 100 例患者治疗中,dMT 组的优良结局患者数比 MT+IVT 组多 10 例。
这项包含 7 项 RCTs 的荟萃分析显示,对于近端前循环闭塞引起的缺血性脑卒中患者,MT 在疗效和安全性结局方面与桥接治疗相当,无论地理位置如何。这些发现支持在急性缺血性脑卒中治疗中采用 dMT,在全球应用中具有更高的成本效益。